HLA-G and amyloidosis: MM who did not enter the subsequent LOT were significantly older, presented higher levels of β2-microglobulin and LDH, and had higher incidences of anemia, thrombocytopenia, renal insufficiency and comorbidities such as amyloidosis, pulmonary diseases, hepatic diseases, and cardiac disorders.